Publications

This issue explores Massachusetts’ trends in psychotropic medication prescriptions, including medications for substance use disorder (SUD), among commercially-insured Massachusetts residents between the ages of 5 and 64 with full-year pharmacy coverage in the Massachusetts All-Payer Claims Database from 2019 – 2024.

This issue of the HPC’s DataPoints explores commercial health care claim denials in Massachusetts, the vast majority of which were for administrative reasons, such as duplicate or incomplete claims or other submission errors.

This issue of the HPC’s DataPoints examines rising patient cost sharing, out-of-pocket and often unpredictable health care costs that Massachusetts residents pay.

This issue of the HPC’s DataPoints series identifies pharmacy deserts – communities without convenient access to a pharmacy and the medication and services they provide – across the state, as well as “near-deserts” – communities that are vulnerable to becoming pharmacy deserts.

This issue of the HPC’s DataPoints series examines the relative commercial prices for primary care services as compared to common specialty services to better understand and quantify existing payment disparities.

This issue of the HPC's DataPoints series explores trends in polypharmacy, or the use of five or more prescription medications, among commercially-insured adults in Massachusetts, including the characteristics of individuals with polypharmacy and trends in their care utilization.

This issue of the HPC’s DataPoints series provides key facts about the 17 ACOs that were recertified by the HPC in either December 2023 or December 2024 (“Certified ACOs”), with a focus on their risk contracts and the care delivery innovations made possible by them.

This issue of the HPC’s DataPoints series explores trends in GLP-1 prescriptions in Massachusetts through September 2023 and examines the use and spending impacts of these drugs in the Commonwealth.

This issue of the HPC’s DataPoints series analyzes the ASC landscape in Massachusetts including the location and services provided by ASCs, utilization among commercial and MassHealth patients, and prices in ASCs compared to HOPDs, as well as the regulatory context that has shaped the ASC industry in the Commonwealth.

This issue explores where commercially-insured residents in Massachusetts received flu vaccines between 2017 and 2021, and aims to increase understanding of differences in access and spending related to cost of flu vaccines among commercially-insured residents across the Commonwealth.